Pharma BD Deal Intelligence
Women health and animal health assets briefly held before Merck absorption
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Schering-Plough acquired Organon BioSciences N.V. from Akzo Nobel in 2007 for approximately $14.4 billion in cash, gaining Organon's human-pharmaceuticals franchise in women's health and central nervous system disorders along with the Intervet animal-health business. The acquisition, completed in November 2007, expanded Schering-Plough's specialty pipeline and global footprint.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Schering-Plough Corp. / Organon & Co. (this deal) | 2007 | $14.4B | 48 |
| Schering-Plough Corp. / Organon International | 2007 | $14.4B | 56 |
| Schering-Plough Corp. / Organon BioSciences N.V. (Akzo Nobel) | 2007 | $14.5B | 48 |
| Schering-Plough Corp. / NeoGenesis Pharmaceuticals | 2005 | — | 30 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
← Browse all deals · How we score deals
More: 2007 deals · Schering-Plough Corp. deals · Neurology deals